CytomX Therapeutics

CytomX Therapeutics is clinical-stage, oncology-focused biopharmaceutical company with a class of investigational antibody therapeutics based on its Probody? technology platform the treatment of cancer. The company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets, as well as to develop cancer therapeutics difficult-to-drug targets, such as CD166. The company's key product candidate is CX-072, a wholly owned Probody therapeutic targeting programmed cell death ligand 1, a clinically and commercially validated anti-cancer target. The company's second key product candidate is CX-2009, a wholly owned Probody Drug Conjugate against CD166, a tumor antigen.
  • TickerCTMX
  • ISINUS23284F1057
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for CTMX

ValuEngine Rating and Forecast Report for CTMX

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for CTMX

ValuEngine Rating and Forecast Report for CTMX

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

1 director bought

A director at Cytomx Therapeutics Inc bought 9,000 shares at 10.330USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The name...

ValuEngine Rating and Forecast Report for CTMX

ValuEngine Rating and Forecast Report for CTMX

ValuEngine Rating and Forecast Report for CTMX

ValuEngine Rating and Forecast Report for CTMX

ValuEngine Rating and Forecast Report for CTMX

ValuEngine Rating and Forecast Report for CTMX

ValuEngine Rating and Forecast Report for CTMX

ValuEngine Rating and Forecast Report for CTMX

ValuEngine Rating and Forecast Report for CTMX

ValuEngine Rating and Forecast Report for CTMX

ResearchPool Subscriptions

Get the most out of your insights

Get in touch